The report has consulted a number of sources, including venture capitalist André Pienaar, Henry Jackson society fellow Christopher Balding and Roslyn Layton, founder of China Tech Threat. These figures point to the subsidies the company has reportedly received and its opaque ownership model as reasons for a ban. The report adds that the use of Huawei equipment in the UK has caused some consternation from other members of the Five Eyes intelligence-sharing network.
As much as the documents look to criticize Huawei, it also serves as an indictment of successive governments policy toward IT and manufacturing. One of the reasons that Huawei was able to achieve such a large part of the market was because of its low price. This hasn’t been helped by a “lack of diversity across the telecoms supply chain,” which the report says “creates the possibility of national dependence on single suppliers.” The fact that the three major players are Nokia, Ericsson and Huawei is, essentially, not good enough given the current geopolitical situation.
Huawei has already told CNBC that the report “lacks credibility” and is “built on opinion rather than fact.” It added that it expects people to “see through these groundless accusations of collusion,” and instead look at the company’s record over the last two decades.
Back in January, medical device company Masimo levied a lawsuit against Apple, accusing the company of stealing trade secrets and improperly using Masimo inventions related to health monitoring in the Apple Watch.
Masimo is known for its pulse oximetry devices, and Apple just recently debuted the Apple Watch Series 6 with blood oxygen monitoring capabilities. Following the launch of the Series 6, Masimo has accused Apple of attempting to delay the legal proceedings in order to sell more watches and gain a more dominant share of the smart watch market.
As highlighted by Bloomberg, Apple has not officially responded to the original January lawsuit, instead filing requests to dismiss the trade secret part of the case and to have Masimo patents invalidated. Apple has asked the trial court to put the case on hold until the patent issue is resolved, which could take a significant amount of time.
Apple told the court that delaying the case until a patent review will narrow the issues and “reduce wasted resources.” With no hold, the first hearing on the case will take place in April 2021.
According to Masimo, the potential postponement would allow Apple to “seize on a critical window of opportunity to capture an emerging field,” using its “considerable resources and ecosystem” to capture market share with no regard for Masimo patent technology.
Masimo CEO Joe Kiani said in the filing that Masimo believes Apple’s customers see the Series 6 as a “medical product,” which can “harm consumers” and “reduce [Masimo’s] opportunities to sell truly clinical-grade products to consumers.”
Masimo accused Apple of stealing secret information by pretending to have a working relationship with Masimo and then poaching Masimo employees. Masimo also believes that Apple is infringing on 10 Masimo patents, and says that Apple relied on Masimo technology when